Alexion Pharmaceuticals (ALXN) Receives News Impact Rating of 0.16
News headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7446045607945 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Alexion Pharma (ALXN) Announces Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with PNH Presented at ASH (streetinsider.com)
- ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017 (finance.yahoo.com)
- Today’s Brokerage Rating: Alexion Pharmaceuticals, Inc., (NASDAQ: ALXN), Ocera Therapeutics, Inc., (NASDAQ … – Stocks In The News (press release) (tradingnewsnow.com)
- Alexion Pharma (ALXN) Announces Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in … – StreetInsider.com (streetinsider.com)
- Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $876.57 Million (americanbankingnews.com)
Alexion Pharmaceuticals (ALXN) traded down $0.06 during trading on Wednesday, hitting $113.54. The company had a trading volume of 1,873,365 shares, compared to its average volume of 2,298,133. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market capitalization of $25,370.00, a P/E ratio of 22.88, a price-to-earnings-growth ratio of 1.22 and a beta of 1.18.
Several brokerages have weighed in on ALXN. Leerink Swann reissued a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Royal Bank of Canada began coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target for the company. BMO Capital Markets reissued an “outperform” rating and issued a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, Evercore ISI began coverage on Alexion Pharmaceuticals in a report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 price target for the company. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $154.58.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.